Cargando…
Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma
INTRODUCTION: Current prognostic blood-based biomarkers for pancreatic adenocarcinoma (PDAC) are limited. Recently, promoter hypermethylation of SFRP1 (phSFRP1) has been linked to poor prognosis in patients with gemcitabine-treated stage IV PDAC. This study explores the effects of phSFRP1 in patient...
Autores principales: | Stubbe, Benjamin Emil, Larsen, Anders Christian, Madsen, Poul Henning, Krarup, Henrik Bygum, Pedersen, Inge Søkilde, Lundbye-Christensen, Søren, Hansen, Carsten Palnæs, Hasselby, Jane Preuss, Johansen, Astrid Zedlitz, Thorlacius-Ussing, Ole, Johansen, Julia Sidenius, Henriksen, Stine Dam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272559/ https://www.ncbi.nlm.nih.gov/pubmed/37333823 http://dx.doi.org/10.3389/fonc.2023.1211292 |
Ejemplares similares
-
Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma
por: Stubbe, Benjamin Emil, et al.
Publicado: (2021) -
Cell-free DNA promoter hypermethylation in plasma as a predictive marker for survival of patients with pancreatic adenocarcinoma
por: Henriksen, Stine Dam, et al.
Publicado: (2017) -
Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma
por: Henriksen, Stine Dam, et al.
Publicado: (2016) -
The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer
por: Rasmussen, Simon Ladefoged, et al.
Publicado: (2018) -
Hypermethylated DNA, a circulating biomarker for colorectal cancer detection
por: Rasmussen, Simon Ladefoged, et al.
Publicado: (2017)